

Proceedings of the American Society of Clinical Oncology (ASCO) Abstracts

- 25** A phase II study of carboplatin(C) docetaxel (D) & emcyt (E) in patients with hormone refractory prostate cancer (HRPCA). *Abstract 1392, 2000.*
- 26** Phase II study of weekly trimetrexate (TMTX), 5-fluorouracil (5FU) with leucovorin (LV) in patients with metastatic colorectal cancer. *Abstract 1201, 2000.*
- 27** Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). *Abstract 7, 2001.*
- 28** Phase II pilot study of herceptin combined with taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2-neu proto-oncogene a pilot study of the UCLA Network. *Abstract 193, 2001.*
- 29** Open-label, phase I/II dose escalating study of NESP in patients with chronic anemia of cancer. *Abstract 1574, 2001.*
- 30** MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma. *Abstract 56, 2002.*
- 31** MDX-010 (human anti-CTLA4): a phase 1 trial in hormone refractory prostate carcinoma (HRPC). *Abstract 74, 2002.*
- 32** Long-term use of exisulind in men with prostate cancer following radical prostatectomy. *Abstract 733, 2002.*
- 33** Zoledronic acid (Zol) significantly reduces skeletal-related events (SREs) in patients with bone metastases from solid tumors. *Abstract 1179, 2002.*
- 34** A multicenter randomized trial of docetaxel + gemcitabine versus weekly paclitaxel + gemcitabine in patients (pts) with non-small cell lung cancer. *Abstract 1276, 2002.*
- 35** Oxandrolone in cancer-related weight loss (WL): improvement in weight, body cell mass (BCM), performance status and quality of life (QOL). *Abstract 1450, 2002.*
- 36** Darbepoetin alfa effectively alleviates anemia in patients with chronic anemia of cancer: efficacy and pharmacokinetic results of a done-escalation study. *Abstract 1465, 2002.*
- 37** Darbepoetin alfa has higher observed improvements in fatigue and physical well-being than epoetin alfa. *Abstract 2944, 2002.*
- 38** Expanded access single institution clinical program experience with ZD1839 (Iressa™) for patients with advanced non-small cell lung cancer (NSCLC). *Abstract 2705, 2002.*
- 39** Darbepoetin alfa administered every two weeks (Q2W) reduces chemotherapy-induced anemia (CIA) to the same extent as recombinant human erythropoietin (rHuEPO) but with less-frequent dosing. *Abstract 2003, 2003.*
- 40** The burden of weekly epoetin alfa injections to patients and their caregivers. *Abstract 2186, 2003.*
- 41** Long-term efficacy and safety of zoledronic acid in reducing skeletal complications in patients with bone metastases from solid tumors. *Abstract 2532, 2003.*
- 42** Early and sustained improvement in health-related quality of life (HRQOL) was observed with frontloaded darbepoetin alfa compared to conventional therapy. *Abstract 3063, 2003.*
- 43** Safety of oxandrolone in cancer-related weight loss. *Abstract 3013, 2003.*
- 44** A phase 2 randomized study evaluating the timing of darbepoetin alfa administration relative to chemotherapy. *Abstract 3162, 2003.*
- 45** A phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC). *Abstract 4563, 2004.*
- 46** Continuing benefit of zoledronic acid for the prevention of skeletal complications in men with advanced prostate cancer. *Abstract 4575, 2004.*
- 47** Clinical benefit of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer based on history of skeletal complications. *Abstract 4576, 2004.*
- 48** Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on prior history of skeletal complications. *Abstract 7226, 2004.*

Julie Hart & Family Life Looking Through a Screen Door

Getting to the Cause of Anemia



Patrick, Julie & Amanda Hart

For me having anemia as a child was like looking at life through a screen door. Always tired, never understanding why, and no one could explain the underlying causes. It was not until I turned 50 and met Dr. T that the door finally opened. The life long puzzle was solved and Dr. T found the missing piece. I was finally properly diagnosed.

~ Julie Hart ~

Even when she was taking iron pills, Julie Hart never thought much about her chronic anemia. Though she had been diagnosed with it as a child, it was a relatively mild case and did not arouse much suspicion.

But Mrs. Hart's mother, one of Dr. Tchekmedyian's patients who has worked in health care for over 30 years, was concerned. Her active 49-year-old daughter, an executive who was always on the run, appeared sluggish and always seemed to be exhausted. During one of her visits, she mentioned her daughter's difficulties to

Dr. Tchekmedyian and scheduled an initial appointment for her, just to see if there was anything more serious.

Indeed, tests revealed that the deficiency in iron alone could not explain the abnormalities of Mrs. Hart's test results or her degree of fatigue. A subsequent bone marrow test revealed something shocking. More than 95% of the cells in her bone marrow were malignant lymphoma cells. The cancer had almost totally invaded her bone marrow, and its only manifestation was slight anemia and a degree of fatigue.

Despite the shock of her test results, Julie decided to move on, get the proper treatments, and try to resume her normal life.

Until recently, chemotherapy was the only effective treatment for malignant lymphoma. New, more specific treatments that do not entail chemotherapy and are therefore associated with fewer side effects, have recently become available.

Mrs. Hart is responding well to one of these new treatments, the medication rituxan, which is helping her reach her goals. After a few treatments, her blood counts are returning to normal levels, she has more energy, and she is working fulltime again.

"As a physician, there is nothing more rewarding than being able to identify a rather serious condition at the time when it can still be treated without major side effects," says Dr. Tchekmedyian. "It is important to find

out the cause of anemia whenever possible, so that serious conditions are not missed."

Her mother's valid concerns finally led Julie Hart to get the proper diagnosis and treatment.



Happy to have more energy



Julie's children Patrick & Amanda...never too old to play. That's why we have frequent family nights.